Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SGMT files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsSagimet grants CEO 300k stock options and 300k performance RSUs tied to regulatory milestones
Filed June 3, 2026 · Period ending May 28, 2026 · ~1 min read
Key Changes
-
medium
CEO David Happel received 300,000 stock options at $7.27/share and 300,000 performance-based RSUs, the largest equity grant among three executives awarded on May 28, 2026.
Item 5.02 verify on EDGAR → -
medium
Performance RSUs vest only upon achieving unspecified regulatory milestones, with one-third vesting at achievement and two-thirds over the following two years, directly tying executive pay to drug development progress.
Item 5.02 verify on EDGAR → -
low
CFO Thierry Chauche and Chief Legal Officer Elizabeth Rozek received 50,000 and 100,000 options/PSUs respectively, with identical vesting terms.
Item 5.02 verify on EDGAR → -
low
Stock options vest monthly over 48 months at $7.27 exercise price, matching the closing price on grant date, representing standard time-based retention incentives.
Item 5.02 verify on EDGAR →
Summary
Sagimet disclosed executive compensation grants totaling 450,000 stock options and 450,000 performance-based restricted stock units across three officers. The CEO's 600,000-unit package represents the most significant award. Notably, the performance RSUs are tied to achieving regulatory milestones—likely FDA approvals or clinical trial endpoints—though the specific targets weren't disclosed in this filing.
For retail investors, this matters because it aligns management incentives with the company's drug development pipeline. The performance-based structure means executives only earn roughly half their equity if Sagimet hits key regulatory goals. The staggered vesting after milestone achievement also ensures leadership retention through critical commercialization phases.
Watch for upcoming clinical trial results or FDA submissions that could trigger these performance milestones. The company will likely disclose when PSUs vest, providing visibility into which regulatory goals have been achieved and potentially signaling progress toward product approval.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 28, 2026 (the “Grant Date”), the Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of Sagimet Biosciences Inc. (the “Company”) and the Board, as applicable, granted options (the “Options”) to purchase shares of the Company’s Series A common stock, par value $0.0001 per share (the “Common Stock”), and performance-based restricted stock units (“PSUs”) to David Happel, the Company’s President and Chief Executive Officer, Thierry Chauche, the Company’s Chief Financial Officer, and Elizabeth Rozek, Esq., the Company’s Chief Legal and Administrative Officer (the “Officers”). Mr. Happel was awarded 300,000 options and 300,000 PSUs, Mr. Chauche was awarded 50,000 options and 50,000 PSUs and Ms. Rozek was awarded 100,000 options and 100,000 PSUs.
The company granted equity compensation to three executive officers on May 28, 2026. CEO David Happel received 300,000 stock options and 300,000 performance-based restricted stock units. CFO Thierry Chauche received 50,000 options and 50,000 PSUs, while Chief Legal Officer Elizabeth Rozek received 100,000 options and 100,000 PSUs. All awards were granted under the company's 2023 Stock Option and Incentive Plan.
Added in current filing · verify on EDGAR →
The Officers will earn a percentage of such PSU award upon the Company’s achievement of certain regulatory milestones, and, in each case, one-third of such earned portion shall vest upon the Compensation Committee’s determination of the achievement of such regulatory milestones (the “Achievement Determination Date”) and the remaining two-thirds will vest in two equal installments on the first and second anniversaries of such Achievement Determination Date.
The performance-based restricted stock units are tied to achieving unspecified regulatory milestones. Once a milestone is achieved and certified by the Compensation Committee, one-third of the earned PSUs vest immediately, with the remaining two-thirds vesting in equal portions on the first and second anniversaries of that determination date. This structure aligns executive compensation with regulatory progress while ensuring retention.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Each Option has an exercise price of $7.27 per share, which is equal to the closing stock price of the Company’s Common Stock on the Grant Date, and vests in equal installments over 48 months.
The stock options have an exercise price of $7.27 per share, matching the closing stock price on the grant date. The options vest equally over 48 months, meaning executives will gain the right to exercise 1/48th of their options each month over four years.
Event · Item 9.01 — Financial Statements and Exhibits
Sagimet filed an 8-K to disclose a new form of performance-based restricted stock unit award agreement.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Form of Performance-Based Restricted Stock Unit Award Agreement.
The company has adopted a new form agreement for granting performance-based restricted stock units to employees or executives. This is a routine compensation document that establishes the terms under which equity awards vest based on achievement of performance metrics.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 4, 2026 · How we verify